Preprocedural circulating galectin-3 and the risk of mortality after transcatheter aortic valve replacement : a systematic review and meta-analysis
© 2020 The Author(s)..
BACKGROUND: Galectin-3 may predict mortality for patients with aortic stenosis (AS) after transcatheter aortic valve replacement (TAVR). However, the results were inconsistent. We aimed to evaluate the association between baseline galectin and mortality after TAVR in a meta-analysis.
METHODS: Related follow-up studies were obtained by systematic search of PubMed, Cochrane's Library, and Embase databases. Both the fixed- and the random-effect models were used for the meta-analysis. Subgroup analyses were performed to evaluate the influences of study characteristics on the outcome.
RESULTS: Five prospective cohort studies with 854 patients were included, with a follow-up period between 1 and 1.9 years. Patients with higher baseline circulating galectin-3 had an increased risk of all-cause mortality after TAVR (random-effects model: risk ratio [RR]: 1.63, 95% confidence interval [CI]: 1.19-2.23, P=0.002; fixed-effects model: RR: 1.62, 95% CI: 1.19-2.20, P=0.002; I2 = 4%). Adjustment of estimated glomerular filtration rate (RR: 1.73, P=0.02) or B-type natriuretic peptide (BNP) or N-terminal pro-BNP (RR: 1.83, P=0.02) did not significantly affect the result. A trend of stronger association between higher baseline circulating galectin-3 and increased risk of all-cause mortality after TAVR was observed in studies with an enzyme-linked fluorescent assay (ELFA) (RR: 3.04, P=0.003) compared with those with an enzyme-linked immunosorbent assay (ELISA) (RR: 1.42, P=0.04; P for subgroup difference =0.06).
CONCLUSION: Higher circulating galectin-3 before the procedure may predict all-cause mortality of AS patients after TAVR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Bioscience reports - 40(2020), 9 vom: 30. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Hong-Liang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aortic stenosis |
|---|
| Anmerkungen: |
Date Completed 29.03.2021 Date Revised 29.03.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1042/BSR20202306 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314665765 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314665765 | ||
| 003 | DE-627 | ||
| 005 | 20231225153224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1042/BSR20202306 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314665765 | ||
| 035 | |a (NLM)32893848 | ||
| 035 | |a (PII)BSR20202306 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Hong-Liang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preprocedural circulating galectin-3 and the risk of mortality after transcatheter aortic valve replacement |b a systematic review and meta-analysis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2021 | ||
| 500 | |a Date Revised 29.03.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Author(s). | ||
| 520 | |a BACKGROUND: Galectin-3 may predict mortality for patients with aortic stenosis (AS) after transcatheter aortic valve replacement (TAVR). However, the results were inconsistent. We aimed to evaluate the association between baseline galectin and mortality after TAVR in a meta-analysis | ||
| 520 | |a METHODS: Related follow-up studies were obtained by systematic search of PubMed, Cochrane's Library, and Embase databases. Both the fixed- and the random-effect models were used for the meta-analysis. Subgroup analyses were performed to evaluate the influences of study characteristics on the outcome | ||
| 520 | |a RESULTS: Five prospective cohort studies with 854 patients were included, with a follow-up period between 1 and 1.9 years. Patients with higher baseline circulating galectin-3 had an increased risk of all-cause mortality after TAVR (random-effects model: risk ratio [RR]: 1.63, 95% confidence interval [CI]: 1.19-2.23, P=0.002; fixed-effects model: RR: 1.62, 95% CI: 1.19-2.20, P=0.002; I2 = 4%). Adjustment of estimated glomerular filtration rate (RR: 1.73, P=0.02) or B-type natriuretic peptide (BNP) or N-terminal pro-BNP (RR: 1.83, P=0.02) did not significantly affect the result. A trend of stronger association between higher baseline circulating galectin-3 and increased risk of all-cause mortality after TAVR was observed in studies with an enzyme-linked fluorescent assay (ELFA) (RR: 3.04, P=0.003) compared with those with an enzyme-linked immunosorbent assay (ELISA) (RR: 1.42, P=0.04; P for subgroup difference =0.06) | ||
| 520 | |a CONCLUSION: Higher circulating galectin-3 before the procedure may predict all-cause mortality of AS patients after TAVR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Aortic stenosis | |
| 650 | 4 | |a Galectin-3 | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Transcatheter aortic valve replacement | |
| 650 | 7 | |a Blood Proteins |2 NLM | |
| 650 | 7 | |a Galectins |2 NLM | |
| 650 | 7 | |a LGALS3 protein, human |2 NLM | |
| 700 | 1 | |a Song, Guang-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yu-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Mo-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yan-Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Bin-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Guan-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhi-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yong-Jian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioscience reports |d 1981 |g 40(2020), 9 vom: 30. Sept. |w (DE-627)NLM01264465X |x 1573-4935 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2020 |g number:9 |g day:30 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1042/BSR20202306 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2020 |e 9 |b 30 |c 09 | ||